176 related articles for article (PubMed ID: 19024526)
21. [Gefitinib in the treatment of male patients with advanced non-small-cell lung cancer].
Wang B; Zhang XR; Chu DT
Zhonghua Zhong Liu Za Zhi; 2007 Jul; 29(7):549-51. PubMed ID: 18069641
[TBL] [Abstract][Full Text] [Related]
22. [Efficacy of endostar combined with chemotherapy in multi-cycle treatment of patients with advanced non-small cell lung cancer].
Li N; Jin ZL; Liu ZJ; Wang J; Li K
Zhonghua Zhong Liu Za Zhi; 2011 Dec; 33(12):937-42. PubMed ID: 22340106
[TBL] [Abstract][Full Text] [Related]
23. [Value of serum carcinoembryonic antigen in prediction of chemotherapy efficacy and prognosis in patients with advanced non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitor].
Xu CA; Su H; Liu JL; Li L; Zou HW
Zhonghua Zhong Liu Za Zhi; 2011 Jun; 33(6):436-41. PubMed ID: 21875484
[TBL] [Abstract][Full Text] [Related]
24. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.
Herbst RS; Prager D; Hermann R; Fehrenbacher L; Johnson BE; Sandler A; Kris MG; Tran HT; Klein P; Li X; Ramies D; Johnson DH; Miller VA;
J Clin Oncol; 2005 Sep; 23(25):5892-9. PubMed ID: 16043829
[TBL] [Abstract][Full Text] [Related]
25. Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study.
Reck M; van Zandwijk N; Gridelli C; Baliko Z; Rischin D; Allan S; Krzakowski M; Heigener D
J Thorac Oncol; 2010 Oct; 5(10):1616-22. PubMed ID: 20736854
[TBL] [Abstract][Full Text] [Related]
26. Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.
Kim ST; Uhm JE; Lee J; Sun JM; Sohn I; Kim SW; Jung SH; Park YH; Ahn JS; Park K; Ahn MJ
Lung Cancer; 2012 Jan; 75(1):82-8. PubMed ID: 21684626
[TBL] [Abstract][Full Text] [Related]
27. [IRESSA in the treatment of advanced non-small-cell lung cancer patients who failed to respond previous chemotherapy].
Wang B; Zhang XR; Chu DT
Zhonghua Zhong Liu Za Zhi; 2004 Dec; 26(12):742-5. PubMed ID: 15733394
[TBL] [Abstract][Full Text] [Related]
28. A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705.
Yoshioka H; Hotta K; Kiura K; Takigawa N; Hayashi H; Harita S; Kuyama S; Segawa Y; Kamei H; Umemura S; Bessho A; Tabata M; Tanimoto M;
J Thorac Oncol; 2010 Jan; 5(1):99-104. PubMed ID: 19898258
[TBL] [Abstract][Full Text] [Related]
29. Three cases of long-lasting tumor control with erlotinib after progression with gefitinib in advanced non-small cell lung cancer.
Gridelli C; Maione P; Galetta D; Colantuoni G; Del Gaizo F; Ferrara C; Guerriero C; Nicolella D; Rossi A
J Thorac Oncol; 2007 Aug; 2(8):758-61. PubMed ID: 17762344
[TBL] [Abstract][Full Text] [Related]
30. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.
Cappuzzo F; Ciuleanu T; Stelmakh L; Cicenas S; Szczésna A; Juhász E; Esteban E; Molinier O; Brugger W; Melezínek I; Klingelschmitt G; Klughammer B; Giaccone G;
Lancet Oncol; 2010 Jun; 11(6):521-9. PubMed ID: 20493771
[TBL] [Abstract][Full Text] [Related]
31. Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.
Johnson JR; Cohen M; Sridhara R; Chen YF; Williams GM; Duan J; Gobburu J; Booth B; Benson K; Leighton J; Hsieh LS; Chidambaram N; Zimmerman P; Pazdur R
Clin Cancer Res; 2005 Sep; 11(18):6414-21. PubMed ID: 16166415
[TBL] [Abstract][Full Text] [Related]
32. Maintenance erlotinib versus erlotinib at disease progression in patients with advanced non-small-cell lung cancer who have not progressed following platinum-based chemotherapy (IUNO study).
Cicènas S; Geater SL; Petrov P; Hotko Y; Hooper G; Xia F; Mudie N; Wu YL
Lung Cancer; 2016 Dec; 102():30-37. PubMed ID: 27987585
[TBL] [Abstract][Full Text] [Related]
33. Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer.
Papadimitrakopoulou VA; Soria JC; Jappe A; Jehl V; Klimovsky J; Johnson BE
J Thorac Oncol; 2012 Oct; 7(10):1594-601. PubMed ID: 22968184
[TBL] [Abstract][Full Text] [Related]
34. Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2.
Lilenbaum R; Axelrod R; Thomas S; Dowlati A; Seigel L; Albert D; Witt K; Botkin D
J Clin Oncol; 2008 Feb; 26(6):863-9. PubMed ID: 18281658
[TBL] [Abstract][Full Text] [Related]
35. Randomized phase 2b study of pralatrexate versus erlotinib in patients with stage IIIB/IV non-small-cell lung cancer (NSCLC) after failure of prior platinum-based therapy.
Kelly K; Azzoli CG; Zatloukal P; Albert I; Jiang PY; Bodkin D; Pereira JR; Juhász E; Iannotti NO; Weems G; Koutsoukos T; Patel JD
J Thorac Oncol; 2012 Jun; 7(6):1041-8. PubMed ID: 22534814
[TBL] [Abstract][Full Text] [Related]
36. Second-line erlotinib in patients with advanced non-small-cell lung cancer: subgroup analyses from the TRUST study.
Heigener DF; Wu YL; van Zandwijk N; Mali P; Horwood K; Reck M
Lung Cancer; 2011 Nov; 74(2):274-9. PubMed ID: 21439671
[TBL] [Abstract][Full Text] [Related]
37. A phase II study of erlotinib as initial treatment for patients with stage IIIB-IV non-small cell lung cancer.
Akerley W; Boucher KM; Bentz JS; Arbogast K; Walters T
J Thorac Oncol; 2009 Feb; 4(2):214-9. PubMed ID: 19179899
[TBL] [Abstract][Full Text] [Related]
38. Use of the epidermal growth factor receptor inhibitors gefitinib and erlotinib in the treatment of non-small cell lung cancer: a systematic review.
Feld R; Sridhar SS; Shepherd FA; Mackay JA; Evans WK;
J Thorac Oncol; 2006 May; 1(4):367-76. PubMed ID: 17409886
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness of erlotinib as a second line therapy for patients with epidermal growth factor receptor (EGFR) mutation in non-small cell lung cancer (NSCLC): our clinical experience.
Crvenkova S; Ivkovski Lj; Dimovski A; Kaeva B
Prilozi; 2012; 33(1):303-11. PubMed ID: 22983065
[TBL] [Abstract][Full Text] [Related]
40. Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer.
Pérez-Soler R; Chachoua A; Hammond LA; Rowinsky EK; Huberman M; Karp D; Rigas J; Clark GM; Santabárbara P; Bonomi P
J Clin Oncol; 2004 Aug; 22(16):3238-47. PubMed ID: 15310767
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
